Development of SA-533 Type B CL. 1+SA-240 Type 304L roll-bonded clad steel plate for safety injection tank of CAP1400 nuclear power plant

Aiming to meet the demand of the country＇ s nuclear demonstration project on the CAP1400 nuclear power plant, Baosteel uses the roll-bonding technology and develops the SA-533 Type B CL. 1 ＋ SA-240 Type 304L high-strength and high-toughness clad steel plate with a shear strength of over 310 MPa for the nuclear power plant＇ s safety injection tank. The properties of the quenched and tempered and the simulated post-weld heat treatment states are systematically studied herein through a comprehensive inspection and evaluation of the composition,microstructure,and properties of the clad steel plate. The results show that the bonding interface has high shear strength and that the base metal has high strength and good toughness at low temperatures. Hence, the performance fully meets the technical requirements of the CAP1400 nuclear power plant＇ s safety injection tank in the country＇ s nuclear demonstration project. The roll-bonded clad steel plate can be used to manufacture the safety injection tank of the CAP1400 nuclear power plant.

Optic diagnosis of neutral beam injection on HL-1M

During the operation of a high-power neutral beam injection (NBI) system on theHL-1M tokamak, an optical diagnostic means using CCD camera was developed to characterize theNBI performance. The vacuum valve opening process and NBI period in the HL-1M experimentwere displayed by a lot of photos taken with this means. Thus, the Hα emission profiles of theneutral beam (NB) and its interaction with plasma were given. Finally, the reason possible forplasma breakdown during NBI mode Ⅱ discharge was investigated. Therefore, this in-situ diagnosiscan provide more information of the NBI.

Fuelling and Diagnostics with Pellet Injection in the HL-1M Tokamak

The pellet injection experiments for fuelling and diagnostics have been carried out on the HL-1M tokamak. The eight-pellet injector was installed on HL-1M. A reliable monitordetector and camera system was set up to take initial pellet photographs and measure the initial pellet speed and size. High fuelling efficiency of 60 % - 100 % and a density profile with a peaking factor of 1.8 - 2.0 were obtained. The maximum density close to 10^14/cm^3 in HL-1M was achieved with newly optimized combined fuelling techniques. Two typical models of pellet ablation have been utilized for simulative calculation of the ablation rates in HL-1M. In comparison with the distribution of the measured Hα emission intensity from the digital data of the CCD camera, the experimental result seems more optimistic for core fuelling than theoretical predictions by the two models. The safety factor profile q（r） has been extracted from the information provided by the CCD camera during the pellet injection. The reliability of the measured results depends mainly on the calibration of the imaging space position. Based on the calibration, the measured q-profile becomes more reasonable than those published previously for the same shot number and same photograph.

Effects of astragalus injection on the skin lesion degree and Caspase-14,SOCS1 and STAT3 levels of psoriasis model in Balb/c nude mice

Objective: To investigate the effect of Astragalus Injection on the Skin Lesion Degree and Caspase-14, SOCS1 and STAT3 Levels of Psoriasis Model in Balb/c Nude Mice. Methods:Sixty Balb/c nude mice were randomly divided into groups A, B and C with 20 mice in each group. Group A mice were used as blank control, group B mice as model group and group C mice as treatment group. The PASI score of psoriasis, skin thickness, inflammatory factors, serum levels of Caspase-14, SOCS1 and STAT3 in three groups of mice were analyzed after 2 weeks of treatment. Result: After treatment, the P ASI score of group B was significantly higher than that of group C, with statistical significance (P < 0.05);there was statistical significance in the measurements of lesion skin of three groups of mice after treatment (P <0.05). Compared with the blank control group, the thickness of lesion skin in group B and C was significantly higher, and the thickness of lesion skin in treatment group was significantly lower than that in control group (P < 0.05). Compared with the blank control group, the inflammatory factors IL-17, IL-22 and IL-23 in the B and C groups were significantly increased, and the inflammatory factors IL-17, IL-22 and IL-23 in the treatment group were significantly lower than those in the model group. The levels of serum C aspase-14, SOCS1 and STAT3 in three groups of mice were significantly different after treatment (P < 0.05). Compared with the blank control group, the levels of serum C aspase-14 and SOCS1 in B and C groups were significantly lower and the levels of STAT3 were significantly higher, and the levels of inflammatory factors aspase-14 and SO in treatment group were significantly higher than those in control group. The level of CS1 was significantly lower than that of model group, and the level of STAT3 was significantly higher than that of model group (P <0.05). Conclusion: Astragalus membranaceus injection can effectively improve the degree of psoriasis in Balb/c nude mice. Its possible mechanism is that it can decrease the expression of Caspase-14 and SOCS1, reduce the degree of keratosis in the lesion site of mice, improve the local surface hyperplasia, increase the level of STAT3 and enhance the level of local cell proliferation, which is of positive significance for the rehabilitation of psoriasis.

Clinical efficacy of Danshen injection in combined with local injection of triamcinolone acetonide in the treatment of oral submucous fibrosis and the effect on serum TGF-β1 and IL-6

Objective:To explore the clinical efficacy of Danshen injection in combined with local injection of triamcinolone acetonide in the treatment of oral submucous fibrosis (OSF) and the effect on serum TGF-β1 and IL-6.Methods:A total of 70 patients with OSF who were admitted in our hospital from October, 2015 to October, 2016 were included in the study and randomized into the observation group and the control group (n=35). The patients in the control group were given multipoint injection of triamcinolone acetonide (40 mg/time) in the basal region of oral mucosal regions. On this basis, the patients in the observation group were given additional Danshen injection (4 mL/time), 1 time/week, for 12 times. VAS was used for evaluation. The oral mucosa lesion area and mouth opening were measured. The morning fasting peripheral venous blood before and after treatment in the two groups was collected. The blood rheometer was used to detect the whole blood viscosity [high shear (HS), moderate shear (MS), and low shear (LS)], plasma viscosity (PV), and fibrinogen (FIB). ELISA was used to detect the serum TGF-β1 and IL-6 levels.Results: VAS score in the observation group was significantly reduced (P<0.05), mucosal lesion area was significantly less than that in the control group (P<0.05), and mouth opening was significantly greater than that in the control group (P<0.05). LS, MS, PV, and FIB after treatment in the observation group were significantly reduced when compared with before treatment (P<0.05), while LS, MS, HS, PV, and FIB after treatment in the control group were not significantly changed (P>0.05). TGF-β1 and IL-6 levels after treatment in the observation group were significantly lower than those in the control group (P<0.05).Conclusions: Danshen injection in combined with local injection of triamcinolone acetonide in the treatment of OSF can effectively reduce the serum TGF-β1 and IL-6 levels, inhibit the connective tissue fibrosis, and improve the pain, oral mucosal lesion area, and mouth opening, with a satisfactory clinical effect.

血必净联合胸腺肽α_1治疗烧伤脓毒症患者的临床疗效

目的评价血必净联合胸腺肽α1对烧伤脓毒症患者的治疗作用。方法将112例脓毒症患者随机分成4组:血必净组、胸腺肽α1组、血必净加胸腺肽α1组、对照组。治疗前、后抽取静脉血测定脂多糖(LPS)、TNF-α,并观察心率、白细胞计数等指标变化。结果血必净加胸腺肽α1组各项指标下降幅度均大于其余3组(P<0.05)。结论血必净联合胸腺肽α1能明显减轻全身炎性反应,促进免疫功能的恢复,显著改善病情。

胸腺肽α_1对恶性肿瘤患者化疗期间免疫功能影响

目的：观察胸腺肽α1（Tα1）对化疗期间恶性肿瘤患者的免疫功能影响。方法：20例晚期恶性肿瘤患者随机分成A，B两组。A组给予单一化疗；B组在化疗同时给予Tα11．6mg／次，sc，2次／周，连用2个月。两组病例在治疗前后分别用流式细胞仪测定外周血T细胞亚群（CD3，CD4，CD8及CD4／CD8）和NK细胞活性。结果：B组的CD4，CD4／CD8和NK细胞活性治疗后明显高于治疗前，有统计学意义（P＜0．05）。治疗后A，B两组相比，B组的NK细胞活性明显高于A组，有统计学意义（P＜0．05）。结论：Tα1能明显提高肿瘤患者的免疫功能，特别对提高NK细胞活性尤为明显，并且没有发现明显的毒副作用，是一种低毒高效的生物反应调节剂。

胸腺素α_1 基因的克隆表达及其生物活性

胸腺素α1(thymosinalpha 1 ,Tα1)作为一种免疫增强剂 ,临床用途广泛 .为大量制备Tα1,按大肠杆菌惯用密码子合成Tα1基因 ,克隆于质粒pUC1 9的EcoRⅠ和PstⅠ位点 .经测序证明序列正确后 ,串联为 4串体 (Tα1④ ) ,经再次测序确认后克隆入pThioHisA的EcoRⅠ和PstⅠ位点 .转化大肠杆菌T0P1 0 ,酶切鉴定正确后 ,经 1mmol LIPTG诱导 4h ,获得硫氧还蛋白与Tα1④的融合表达 ,用离子交换层析纯化融合蛋白 .溴化氰裂解融合蛋白 ,释放出Tα1单体 ,经离子交换色谱纯化出Tα1.采用3 H TdR参入法进行生物活性测定 ,证实融合蛋白和Tα1均具有刺激小鼠脾淋巴细胞分裂增殖的能力 .

阿德福韦酯联合胸腺肽α_1与单用阿德福韦酯比较治疗慢性乙肝的系统评价

目的系统评价阿德福韦酯联合胸腺肽α1(ADF+Tα1)与单用阿德福韦酯比较治疗慢性乙型肝炎的疗效。方法电子检索Cochrane图书馆、MEDLINE、PubMed、中国生物医学文献数据库、CNKI、万方、VIP数据库,均从建库检索至2010年2月,并追踪已获文献的参考文献,纳入ADF+Tα1与单用ADF比较的随机对照试验(RCT)。由2名研究者按照Cochrane Handbook 5.0.2手册独立纳入试验、评价质量及提取数据,采用RevMan5.0软件进行Meta分析。结果最终纳入11个RCT,共895例患者,其方法学质量均为C级。Meta分析结果显示:主要结局指标(HBeAg血清转换)在治疗6个月、12个月时,试验组均优于对照组,其差异有统计学意义[RR(95%CI)分别为1.77(1.38,2.27)和1.74(1.44,2.10)];次要结局指标(HBV-DNA转阴、HBeAg转阴、ALT复常、HBV-DNA变异,完全应答、HBsAg阴转)在治疗6个月、12个月后,试验组也均优于对照组,且差异有统计学意义。结论本系统评价结果表明,ADF+Tα1治疗慢性乙型肝炎疗效优于单用ADF,且在治疗6个月时便可观察到明显差异,但受纳入文献质量限制,以上结论尚需高质量的临床试验进一步证实。

生脉联合胸腺肽α_1对高龄医院获得性重症肺炎患者细胞免疫功能及预后的影响

目的观察和评价生脉联合胸腺肽α1对高龄医院获得性重症肺炎患者细胞免疫功能及预后的影响。方法将重症监护室内高龄医院获得性重症肺炎患者随机分为对照组和治疗组。对照组采取常规治疗,而治疗组使用常规治疗+生脉联合胸腺肽α1治疗2周。观察并比较治疗前后2组慢性健康评分系统(APACHEⅡ)评分、器官功能障碍(Mar-shall)评分、ICU住院时间及28 d病死率;采用流式细胞术检测外周血T细胞亚群(CD3+、CD4+、CD8+、CD3+/CD4+)的表达水平。结果治疗后治疗组患者CD3+、CD4+表达水平显著高于对照组,CD8+表达水平低于对照组。APACHEⅡ评分、Marshall评分均低于对照组,ICU住院时间短于对照组,但28 d病死率2组比较无显著性差异。结论生脉联合胸腺肽α1能增强高龄医院获得性重症肺炎患者的免疫防御能力,改善预后,缩短其住院时间,但未能显著降低病死率。

合成胸腺素α_1的生物活性研究

利用固相多肽合成中的 Boc和 Fmoc途径分别合成了胸腺素α1 (S- Tα1 )。后者的合成产率 (去保护基后粗肽量 /理论量 )为 80 % ,大于前者的 64.2 %。在 Fmoc方法合成中 ,用 Fmoc- Asn(Trt)上羟基树脂 (HMP树脂 )提高了合成产率。经 FPLC纯化后 ,Tα1 用 HPLC、毛细管电泳、等电聚焦电泳鉴定纯度均一 ;质谱和 N端序列分析证明其符合理论值。Tα1 活性测定 ,表明 S- Tα1 能提高淋巴细胞对丝裂原刺激的增殖反应 ,增强 NK细胞杀伤活性 ,具有增加淋巴细胞产生 IFN- γ的作用 ,我们的合成产物与国外对照品 Z- Tα1 呈现相仿的活性。此工作为进一步研究 Tα1

胸腺肽α_1联合康艾注射液对肝细胞癌患者TACE术后细胞免疫功能的影响

目的观察联合使用胸腺肽α1和康艾注射液对肝细胞癌患者经肝动脉化疗栓塞术(TACE)术后细胞免疫功能的影响。方法随机选取我科住院的肝细胞癌行TACE治疗患者51例,分为A、B两组,A组26例术后第1天开始联合使用胸腺肽α1及康艾注射液进行一个疗程治疗,B组25例除不使用胸腺肽α1外,其他治疗同A组,C组42例为健康体检者。分别在TACE术后第一天胸腺肽α1及康艾注射液治疗前、治疗后1个月应用流式细胞术检测其外周血T淋巴细胞亚群及NK细胞水平。结果肝细胞癌患者细胞免疫功能较正常人显著降低,A组治疗后外周血CD3+、CD4+、CD4+/CD8+比值及NK细胞均明显高于治疗前(P<0.05),而CD8+水平明显低于治疗前(P<0.05),B组治疗前后T淋巴细胞亚群及NK细胞无明显变化(P>0.05)。结论联合使用胸腺肽α1与康艾注射液可提高肝细胞癌患者TACE术后细胞免疫功能。

重组胸腺素α_1的分离纯化和活性测定

目的 利用融合表达载体 p Thio His A的重组质粒p Thio His A- Tα1 4,转化大肠杆菌 TOP10得到的工程菌 ,来分离纯化表达的胸腺素 α1 (thym osin alpha1,Tα1 ) .方法 将高效表达融合蛋白的工程菌用细胞破碎器裂解 ,经 80℃热处理 ,离心上清采用 Q- Sepharose FF阴离子交换色谱纯化融合蛋白 .融合蛋白经 CNBr裂解后用常压离子交换色谱纯化Tα1 单体 .应用 SDS- PAGE,2 L - Tricine- SDS- PAGE和 HPL C进行鉴定 .结果 SDS- PAGE分析表明菌体表达的融合蛋白占菌体总蛋白的 40 0 g· kg- 1 .经 2 L - Tricine- SDS- PAGE分析证实 ,融合蛋白可裂解出 Tα1 单体 ,裂解物经简单的离子色谱可以纯化出 Tα1 单体 ,HPL C鉴定纯化出的 Tα1 纯度可达95 0 g· kg- 1以上 .利用 3H- Td R进行的生物活性测定表明 ,在致有丝分裂原 Con A存在的条件下 ,融合蛋白和 Tα1 单体均具有刺激小鼠脾淋巴细胞分裂增殖的能力 ,与化学合成的Tα1 相比具有相似的生物活性 .结论 该方法是分离纯化Tα1 简便易行 ,经济有效的方法 ;同时也为 Tα1

胸腺肽α_1用于重症肺炎治疗的效果观察

目的探讨胸腺肽α_1用于治疗重症肺炎的效果。方法将56例重症肺炎患者按随机数字表法分为治疗组和对照组,各28例。两组患者入院后均给予常规治疗,治疗组在上述基础上皮下注射1.6 mg胸腺肽α_1,1次/d,持续7 d,分别检测治疗前、治疗第7天患者免疫细胞水平、C反应蛋白((;RP】、血清降钙素原(PCT)、血白细胞计数(WBC)水平的变化。结果两组患者CRP、PCT、WBC和CD8^+较治疗前明显下降(P<0.05),CD4^+、CD4^+/CD8^+比值较治疗前有明显升高;治疗组各指标与对照组比较,差异有统计学意义(P<0.05);治疗组机械通气时间和入住ICU时间明显较对照组短(P<0.05)。结论在常规治疗的基础上使用胸腺肽α_1能提高重症肺炎患者的细胞免疫功能,改善炎症指标,缩短机械通气时间、入住ICU时间。

胸腺肽α_1对严重腹腔感染大鼠蛋白质代谢和细胞因子的影响

目的:观察腹腔感染后胸腺肽α1 (Tα1 )对大鼠细胞因子和蛋白质代谢的影响。 方法:采用盲肠结扎加穿孔(CLP)模型,观察腹腔感染后Tα1 对大鼠血浆细胞因子TNFα、IL 6、IL 10,总蛋白、清蛋白、C反应蛋白(CRP)水平及大鼠氮平衡、病死率的变化。 结果:腹腔感染后大鼠血浆TNFα、IL 6浓度明显高于对照组,IL 10浓度明显低于对照组;给予Tα1 后血浆TNFα、IL 6浓度亦明显高于对照组,但TNFα、IL 6较感染组明显下降,IL 10较感染组明显上升;给予Tα1 后血清蛋白、总蛋白浓度及体质量下降的程度较腹腔感染组明显减轻;血CRP浓度感染组和感染后用Tα1 组明显升高,但给予Tα1 后CRP升高的程度较感染组明显减轻;腹腔感染后大鼠负氮平衡,给予Tα1后5天恢复正氮平衡; 7天累计病死率亦较感染组明显减少。 结论:胸腺肽α1 可改变严重腹腔感染大鼠的细胞因子水平和炎性反应,改善蛋白质代谢。

胸腺肽α_1对慢性支气管炎患者预防呼吸道感染及免疫功能的作用

目的探讨胸腺肽α1(Tα1)对慢性支气管炎(CB)患者呼吸道感染的预防作用及对细胞免疫的影响。方法以28例未注射Tα1的CB患者(对照组)进行同期对照,观察41例CB患者(治疗组)在应用Tα1(1.6mg/次,皮下注射,2次/周,每年春秋季各3个月)治疗2年内发生呼吸道感染情况,并采用流式细胞仪检测治疗前、后T细胞亚群的变化。结果治疗组在Tα1治疗前,外周血CD3、CD4及CD4/CD8下降,CD8升高,经Tα1治疗2年后,外周血CD3、CD4及CD4/CD8回升,CD8下降,而且呼吸道感染的次数、因呼吸道感染应用抗生素的次数及住院次数均较对照组明显减少。结论胸腺肽α1可改善CB患者的细胞免疫功能,减少其呼吸道感染的发生。

重组胸腺素α_1的克隆、表达与纯化

目的 利用基因工程方法表达胸腺素α1 (thymosinalpha1,Tα1 )的串联体并进行纯化、鉴定 .方法 将 Tα1 的基因拆分为 4个片段进行合成 ,退火后经 PCR获得串联体基因 ,测序正确后克隆在硫氧还蛋白 (thioredoxin)融合蛋白表达载体 p Thio His A中 ,转化大肠杆菌 TOP10菌株 ,IPTG诱导表达 ,表达的融合蛋白经过 80℃热处理及阴离子交换柱Q- Sepharose Fast Flow进行纯化 ,Western- blot进行鉴定 .结果 获得了纯化的 Thioredoxin- Tα1 3,分子质量约为 31ku.结论 用基因串联思路表达小分子多肽是一种可行的方法 ,Tα1

人胸腺素α_1基因工程菌的构建与表达

胸腺素α1(Thymosinalpha1,Tα1)是一种针对T淋巴细胞的免疫增强剂,临床用途广泛.为大量制备Tα1,按大肠杆菌惯用密码子合成编码Tα1的基因,克隆于pUCmT,转化E.coliJF1125,经测序证明序列正确后,克隆入pET39(b)的BspT 和BamH 位点,成功地构建出包含信号肽,DsbA,连接肽,6个His,EKsite(Asp-Asp-Asp-Asp-Lys),胸腺素α1的表达载体,转化E.coliBL21(DE3),获得胸腺素α1基因工程菌.SDS-PAGE分析表明,经0.1mmol/LIPTG和30℃诱导8h,在大肠杆菌周质中大量表达表观分子量31kD左右的融合蛋白.为进一步获得大量可供实验研究和临床应用的重组胸腺素α1创造条件.

天然胸腺素α_1基因的克隆及其在大肠杆菌中的表达

目的为降低CNBr裂解融合蛋白的毒副作用 ,改进利用基因重组技术制备胸腺素α1 (Tα1 )的流程工艺。方法按大肠杆菌惯用密码合成Tα1 基因 ,克隆于质粒pGEM 3Zf的EcoRⅠ和PstⅠ位点 ,裂解位点为羟胺裂解位点Asn Gly对应的核苷酸序列 ,测序正确后用BamHⅠ和BglⅡ位点串联为Tα1 4串体 (Tα1 ④ )和Tα1 8串体 (Tα1 ⑧ ) ,经再次测序确认后克隆入pThioHisA的EcoRⅠ和PstⅠ位点 ,转化大肠杆菌TOP1 0。结果经 1mmol LIPTG诱导4h获得了硫氧还蛋白 (thioredoxin)与Tα1 ④和Tα1 ⑧的融合表达 ,用离子交换色谱可纯化出融合蛋白 ,羟胺裂解融合蛋白 ,能够释放出Tα1 单体。结论羟胺能够裂解融合蛋白释放出天然Tα1 。

胸腺肽α_1联合抗结核药物治疗老年肺结核的疗效观察

目的:观察和评价胸腺肽α1联合抗结核药物治疗老年肺结核的疗效。方法:将210例老年肺结核患者随机分为治疗组和对照组,各105例,对照组采用2HRZE/4HR方案治疗,治疗组采用上述方案治疗的同时加用胸腺肽α1,观察临床症状的改善、痰菌阴转、肺部病灶吸收及空洞闭合等情况。结果:两组治疗1个月后症状改善程度均较治疗前有显著改善(P<0.01),治疗后联合组与对照组比较,差异有统计学意义(P<0.01),联合组105例,显效率为86.30%、总有效率为96.5%;对照组105例,显效率为73.58%、总有效率为81.56%,差异有统计学意义。治疗1、2、3个月联合组痰菌阴转率分别为85%(89/105)、91%(95/105)、98%(102/105);对照组痰菌阴转率分别为59%(61/105)、74%(77/105)、86%(90/105)。治疗1、3、6个月联合组105例,病灶吸收总有效率88.6%(93/105)、94.5%(99/105)、99.7%(104/105);对照组105例,病灶吸收总有效率70.6%(74/105)、86.6%(90/105)、90.5%(95/105)。联合组40例空洞者,闭合率是57.5%(23/40)、87.5%(35/40)、95%(38/40);对照组40例空洞者,闭合率是32.5%(13/40)、62.5%(25/40)、77.5%(31/40)。两组比较差异有统计学意义(P<0.01)。结论:胸腺肽α1联合抗结核药物治疗老年肺结核有显著疗效。